Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research

References

• Ma X, Tan C, Zhu D, et al. Huperzine A from Huperzia species–an ethnopharmacolgical review. J Ethnopharmacol. 2007;113(1):15–34.
   PubMed Web of Science ®Google Scholar
• Tang XC, Han YF, Chen XP, et al. [Effects of huperzine A on learning and the retrieval process of discrimination performance in rats]. Zhongguo Yao Li Xue Bao. 1986;7(6):507–511.
   PubMed Web of Science ®Google Scholar
• Ohba T, Yoshino Y, Ishisaka M, et al. Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice. Biosci Biotechnol Biochem. 2015;79:1–7.
   PubMed Web of Science ®Google Scholar
• Wang ZF, Wang J, Zhang HY, et al. Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem. 2008;106(4):1594–1603.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111:85–141.
   PubMed Web of Science ®Google Scholar
• Ma X, Tan C, Zhu D, et al. A survey of potential huperzine A natural resources in China: the Huperziaceae. J Ethnopharmacol. 2006;104(1–2):54–67.
   PubMed Web of Science ®Google Scholar
• Ma X, Tan C, Zhu D, et al. Is there a better source of huperzine A than Huperzia serrata? Huperzine A content of Huperziaceae species in China. J Agric Food Chem. 2005;53(5):1393–1398.
   PubMed Web of Science ®Google Scholar
• Ding R, Sun BF, Lin GQ. An efficient total synthesis of (-)-huperzine A. Org Lett. 2012;14(17):4446–4449.
   PubMed Web of Science ®Google Scholar
• Koshiba T, Yokoshima S, Fukuyama T. Total synthesis of (-)-huperzine A. Org Lett. 2009;11(22):5354–5356.
   PubMed Web of Science ®Google Scholar
• Kozikowski AP, Miller CP, Yamada F, et al. Delineating the pharmacophoric elements of huperzine A: importance of the unsaturated three-carbon bridge to its AChE inhibitory activity. J Med Chem. 1991;34(12):3399–3402.
   PubMed Web of Science ®Google Scholar
• Coleman BR, Ratcliffe RH, Oguntayo SA, et al. [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem Biol Interact. 2008;175(1–3):387–395.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang HY, Tang XC, et al. Effects of synthetic (-)-huperzine A on cholinesterase activities and mouse water maze performance. Zhongguo Yao Li Xue Bao. 1998;19(5):413–416.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wei Y, Oguntayo S, et al. A combination of [+] and [-]-Huperzine A improves protection against soman toxicity compared to [+]-Huperzine A in guinea pigs. Chem Biol Interact. 2013;203(1):120–124.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wei Y, Oguntayo S, et al. [+]-Huperzine A protects against soman toxicity in guinea pigs. Neurochem Res. 2011;36(12):2381–2390.
   PubMed Web of Science ®Google Scholar
• Tang XC, Kindel GH, Kozikowski AP, et al. Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol. 1994;44(3):147–155.
   PubMed Web of Science ®Google Scholar
• McKinney M, Miller JH, Yamada F, et al. Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase. Eur J Pharmacol. 1991;203(2):303–305.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Chen XQ, Yang HH, et al. Similar potency of the enantiomers of huperzine A in inhibition of [(3)H]dizocilpine (MK-801) binding in rat cerebral cortex. Neurosci Lett. 2000;295(3):116–118.
   PubMed Web of Science ®Google Scholar
• Wang XD, Chen XQ, Yang HH, et al. Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex. Neurosci Lett. 1999;272(1):21–24.
   PubMed Web of Science ®Google Scholar
• Viviani B, Bartesaghi S, Gardoni F, et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci. 2003;23(25):8692–8700.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Liang YQ, Tang XC, et al. Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice. Neurosci Lett. 2002;317(3):143–146.
   PubMed Web of Science ®Google Scholar
• Millucci L, Ghezzi L, Bernardini G, et al. Conformations and biological activities of amyloid beta peptide 25-35. Curr Protein Pept Sci. 2010;11(1):54–67.
   PubMed Web of Science ®Google Scholar
• Rees T, Hammond PI, Soreq H, et al. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging. 2003;24(6):777–787.
   PubMed Web of Science ®Google Scholar
• Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer’s disease. Prog Neurobiol. 1997;52(6):511–535.
   PubMed Web of Science ®Google Scholar
• Wang YE, Feng J, Lu WH, et al. [Pharmacokinetics of huperzine A in rats and mice]. Zhongguo Yao Li Xue Bao. 1988;9(3):193–196.
   PubMed Web of Science ®Google Scholar
• Qian BC, Wang M, Zhou ZF, et al. Pharmacokinetics of tablet huperzine A in six volunteers. Zhongguo Yao Li Xue Bao. 1995;16(5):396–398.
   PubMed Web of Science ®Google Scholar
• Li YX, Zhang RQ, Li CR, et al. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet. 2007;32(4):183–187.
   PubMed Web of Science ®Google Scholar
• Ye JC, Zeng S, Zheng GL, et al. Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm. 2008;356(1–2):187–192.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yue P, Tao T, et al. Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats. Acta Pharmacol Sin. 2007;28(2):273–278.
   PubMed Web of Science ®Google Scholar
• Yue P, Tao T, Zhao Y, et al. Huperzine A in rat plasma and CSF following intranasal administration. Int J Pharm. 2007;337(1–2):127–132.
   PubMed Web of Science ®Google Scholar
• Chu DF, Fu XQ, Liu WH, et al. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm. 2006;325(1–2):116–123.
   PubMed Web of Science ®Google Scholar
• Debiopharm G. 2007. Clinical update - Debio 9902 (ZT-1) for Alzheimer’s disease. Available from: https://www.debiopharm.com/medias/press-release/item/2650-clinical-update-debio-9902-zt-1-for-alzheimer.html.
   Google Scholar
• Li C, Du F, Yu C, et al. A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(6):651–656.
   PubMed Web of Science ®Google Scholar
• Jia JY, Zhao QH, Liu Y, et al. Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer’s disease. Acta Pharmacol Sin. 2013;34(7):976–982.
   PubMed Web of Science ®Google Scholar
• Kalaria DR, Patel P, Merino V, et al. Controlled iontophoretic transport of huperzine A across skin in vitro and in vivo: effect of delivery conditions and comparison of pharmacokinetic models. Mol Pharm. 2013;10(11):4322–4329.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen G. Pharmacokinetic behavior of huperzine A in plasma and cerebrospinal fluid after intranasal administration in rats. Biopharm Drug Dispos. 2009;30(9):551–555.
   PubMed Web of Science ®Google Scholar
• Ma X, Wang H, Xin J, et al. Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A. Eur J Pharmacol. 2003;461(2–3):89–92.
   PubMed Web of Science ®Google Scholar
• Garcia GE, Hicks RP, Skanchy D, et al. Identification and characterization of the major huperzine a metabolite in rat blood. J Anal Toxicol. 2004;28(5):379–383.
   PubMed Web of Science ®Google Scholar
• Zhang YW, Bao MH, Wang G, et al. Induction of human CYP3A4 by huperzine A, ligustrazine and oridonin through pregnane X receptor-mediated pathways. Pharmazie. 2014;69(7):532–536.
   PubMed Web of Science ®Google Scholar
• Ma XC, Wang HX, Xin J, et al. Effects of huperzine A on liver cytochrome P-450 in rats. Acta Pharmacol Sin. 2003;24(8):831–835.
   PubMed Web of Science ®Google Scholar
• Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neurosignals. 2005;14(1–2):71–82.
   PubMedGoogle Scholar
• Bisso GM, Briancesco R, Michalek H. Size and charge isomers of acetylcholinesterase in the cerebral cortex of young and aged rats. Neurochem Res. 1991;16(5):571–575.
   PubMed Web of Science ®Google Scholar
• Wade PD, Timiras PS. A regional study of the molecular forms of acetylcholinesterase in the brain of developing and adult rats. Dev Neurosci. 1980;3(3):101–108.
   PubMed Web of Science ®Google Scholar
• Brimijoin S. Molecular forms of acetylcholinesterase in brain, nerve and muscle: nature, localization and dynamics. Prog Neurobiol. 1983;21(4):291–322.
   PubMed Web of Science ®Google Scholar
• Sung SC, Ruff BA. Molecular forms of sucrose extractable and particulate acetylcholinesterase in the developing and adult rat brain. Neurochem Res. 1983;8(3):303–311.
   PubMed Web of Science ®Google Scholar
• Gorenstein C, Gallardo KA, Robertson RT. Molecular forms of acetylcholinesterase in cerebral cortex and dorsal thalamus of developing rats. Brain Res Dev Brain Res. 1991;61(2):271–276.
   PubMedGoogle Scholar
• Koelle GB, Massoulie J, Eugene D, et al. Distributions of molecular forms of acetylcholinesterase and butyrylcholinesterase in nervous tissue of the cat. Proc Natl Acad Sci U S A. 1987;84(21):7749–7752.
   PubMed Web of Science ®Google Scholar
• Xie HQ, Leung KW, Chen VP, et al. PRiMA directs a restricted localization of tetrameric AChE at synapses. Chem Biol Interact. 2010;187(1–3):78–83.
   PubMed Web of Science ®Google Scholar
• Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav. 1998;60(2):377–386.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Tang XC. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol. 2002;455(2–3):101–107.
   PubMed Web of Science ®Google Scholar
• Ashani Y, Peggins JO 3rd, Doctor BP. Mechanism of inhibition of cholinesterases by huperzine A. Biochem Biophys Res Commun. 1992;184(2):719–726.
   PubMed Web of Science ®Google Scholar
• Lallement G, Veyret J, Masqueliez C, et al. Efficacy of huperzine in preventing soman-induced seizures, neuropathological changes and lethality. Fundam Clin Pharmacol. 1997;11(5):387–394.
   PubMed Web of Science ®Google Scholar
• Zoli M, Pistillo F, Gotti C. Diversity of native nicotinic receptor subtypes in mammalian brain. Neuropharmacology. 2015;96(Pt B):302–311.
   PubMed Web of Science ®Google Scholar
• Hurst R, Rollema H, Bertrand D. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther. 2013;137(1):22–54.
   PubMed Web of Science ®Google Scholar
• Albuquerque EX, Pereira EF, Alkondon M, et al. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89(1):73–120.
   PubMed Web of Science ®Google Scholar
• Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 2007;47:699–729.
   PubMed Web of Science ®Google Scholar
• Lukas RJ, Changeux JP, Le Novere N, et al. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev. 1999;51(2):397–401.
   PubMed Web of Science ®Google Scholar
• Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol. 2004;74(6):363–396.
   PubMed Web of Science ®Google Scholar
• Zoli M, Moretti M, Zanardi A, et al. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci. 2002;22(20):8785–8789.
   PubMed Web of Science ®Google Scholar
• Perry DC, Xiao Y, Nguyen HN, et al. Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem. 2002;82(3):468–481.
   PubMed Web of Science ®Google Scholar
• Graham AJ, Ray MA, Perry EK, et al. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J Chem Neuroanat. 2003;25(2):97–113.
   PubMed Web of Science ®Google Scholar
• Bernik TR, Friedman SG, Ochani M, et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med. 2002;195(6):781–788.
   PubMed Web of Science ®Google Scholar
• Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405(6785):458–462.
   PubMed Web of Science ®Google Scholar
• Garcia-Oscos F, Pena D, Housini M, et al. Activation of the anti-inflammatory reflex blocks lipopolysaccharide-induced decrease in synaptic inhibition in the temporal cortex of the rat. J Neurosci Res. 2015;93(6):859–865.
   PubMed Web of Science ®Google Scholar
• Lutz JA, Kulshrestha M, Rogers DT, et al. A nicotinic receptor-mediated anti-inflammatory effect of the flavonoid rhamnetin in BV2 microglia. Fitoterapia. 2014;98:11–21.
   PubMed Web of Science ®Google Scholar
• Pavlov VA, Tracey KJ. Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem Soc Trans. 2006;34(Pt 6):1037–1040.
   PubMed Web of Science ®Google Scholar
• Nikolov R. Alzheimer’s disease therapy - an update. Drug News Perspect. 1998;11(4):248–255.
   PubMedGoogle Scholar
• Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384–388.
   PubMed Web of Science ®Google Scholar
• Stuckenholz V, Bacher M, Balzer-Geldsetzer M, et al. The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. J Parkinsons Dis. 2013;3(2):161–172.
   PubMedGoogle Scholar
• Mencel M, Nash M, Jacobson C. Neuregulin upregulates microglial α7 nicotinic acetylcholine receptor expression in immortalized cell lines: implications for regulating neuroinflammation. PLoS One. 2013;8(7):e70338.
   Google Scholar
• Seguela P, Wadiche J, Dineley-Miller K, et al. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci. 1993;13(2):596–604.
   PubMed Web of Science ®Google Scholar
• Maier DL, Hill G, Ding M, et al. Pre-clinical validation of a novel alpha-7 nicotinic receptor radiotracer, [(3)H]AZ11637326: target localization, biodistribution and ligand occupancy in the rat brain. Neuropharmacology. 2011;61(1–2):161–171.
   PubMed Web of Science ®Google Scholar
• Siek GC, Katz LS, Fishman EB, et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry. 1990;27(6):573–580.
   PubMed Web of Science ®Google Scholar
• Fishman EB, Siek GC, MacCallum RD, et al. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann Neurol. 1986;19(3):246–252.
   PubMed Web of Science ®Google Scholar
• Han Z, Li L, Wang L, et al. Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture. J Neurochem. 2014;131(4):498–508.
   PubMed Web of Science ®Google Scholar
• Kelso ML, Oestreich JH. Traumatic brain injury: central and peripheral role of α7 nicotinic acetylcholine receptors. Curr Drug Targets. 2012;13(5):631–636.
   PubMed Web of Science ®Google Scholar
• Saeed RW, Varma S, Peng-Nemeroff T, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med. 2005;201(7):1113–1123.
   PubMed Web of Science ®Google Scholar
• Wang ZF, Tang XC. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett. 2007;581(4):596–602.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Hu X, Ao H, et al. The neurovascular protective effects of huperzine A on D-galactose-induced inflammatory damage in the rat hippocampus. Gerontology. 2014;60(5):424–439.
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Mata D, Linn DM, et al. Neuroprotection of rat retinal ganglion cells mediated through alpha7 nicotinic acetylcholine receptors. Neuroscience. 2013;237:184–198.
   PubMed Web of Science ®Google Scholar
• Shimohama S, Greenwald DL, Shafron DH, et al. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res. 1998;779(1–2):359–363.
   PubMed Web of Science ®Google Scholar
• Albuquerque EX, Pereira EF, Braga MF, et al. Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of alpha 7 receptors. J Physiol Paris. 1998;92(3–4):309–316.
   PubMed Web of Science ®Google Scholar
• McMahon LL, Yoon KW, Chiappinelli VA. Nicotinic receptor activation facilitates GABAergic neurotransmission in the avian lateral spiriform nucleus. Neuroscience. 1994;59(3):689–698.
   PubMed Web of Science ®Google Scholar
• Arnaiz-Cot JJ, Gonzalez JC, Sobrado M, et al. Allosteric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission. Eur J Neurosci. 2008;27(5):1097–1110.
   PubMed Web of Science ®Google Scholar
• Kawa K. Inhibitory synaptic transmission in area postrema neurons of the rat showing robust presynaptic facilitation mediated by nicotinic ACh receptors. Brain Res. 2007;1130(1):83–94.
   PubMed Web of Science ®Google Scholar
• Buhler AV, Dunwiddie TV. alpha7 nicotinic acetylcholine receptors on GABAergic interneurons evoke dendritic and somatic inhibition of hippocampal neurons. J Neurophysiol. 2002;87(1):548–557.
   PubMed Web of Science ®Google Scholar
• Levey AI, Kitt CA, Simonds WF, et al. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci. 1991;11(10):3218–3226.
   PubMed Web of Science ®Google Scholar
• Foster DJ, Choi DL, Conn PJ, et al. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia. Neuropsychiatr Dis Treat. 2014;10:183–191.
   PubMed Web of Science ®Google Scholar
• Poulin B, Butcher A, McWilliams P, et al. The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci U S A. 2010;107(20):9440–9445.
   PubMed Web of Science ®Google Scholar
• Clader JW, Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer’s disease. Curr Pharm Des. 2005;11(26):3353–3361.
   PubMed Web of Science ®Google Scholar
• Ragozzino ME, Artis S, Singh A, et al. The selective M1 muscarinic cholinergic agonist CDD-0102A enhances working memory and cognitive flexibility. J Pharmacol Exp Ther. 2012;340(3):588–594.
   PubMed Web of Science ®Google Scholar
• Berkeley JL, Gomeza J, Wess J, et al. M1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices. Mol Cell Neurosci. 2001;18(5):512–524.
   PubMed Web of Science ®Google Scholar
• Yi F, Ball J, Stoll KE, et al. Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: roles in cellular excitability, inhibitory transmission and cognition. J Physiol. 2014;592(Pt 16):3463–3494.
   PubMed Web of Science ®Google Scholar
• Gonzalez JC, Albinana E, Baldelli P, et al. Presynaptic muscarinic receptor subtypes involved in the enhancement of spontaneous GABAergic postsynaptic currents in hippocampal neurons. Eur J Neurosci. 2011;33(1):69–81.
   PubMed Web of Science ®Google Scholar
• Peng Y, Lee DY, Jiang L, et al. Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695. Neuroscience. 2007;150(2):386–395.
   PubMed Web of Science ®Google Scholar
• Peng Y, Jiang L, Lee DY, et al. Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells. J Neurosci Res. 2006;84(4):903–911.
   PubMed Web of Science ®Google Scholar
• Zhou J, Tang XC. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett. 2002;526(1–3):21–25.
   PubMed Web of Science ®Google Scholar
• Gao X, Tang XC. Huperzine A attenuates mitochondrial dysfunction in beta-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism. J Neurosci Res. 2006;83(6):1048–1057.
   PubMed Web of Science ®Google Scholar
• Yang L, Ye CY, Huang XT, et al. Decreased accumulation of subcellular amyloid-β with improved mitochondrial function mediates the neuroprotective effect of huperzine A. J Alzheimers Dis. 2012;31(1):131–142.
   PubMed Web of Science ®Google Scholar
• Gao X, Zheng CY, Yang L, et al. Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide. Free Radic Biol Med. 2009;46(11):1454–1462.
   PubMed Web of Science ®Google Scholar
• Lu H, Jiang M, Lu L, et al. Ultrastructural mitochondria changes in perihematomal brain and neuroprotective effects of Huperzine A after acute intracerebral hemorrhage. Neuropsychiatr Dis Treat. 2015;11:2649–2657.
   PubMed Web of Science ®Google Scholar
• Zheng CY, Zhang HY, Tang XC. Huperzine A attenuates mitochondrial dysfunction after middle cerebral artery occlusion in rats. J Neurosci Res. 2008;86(11):2432–2440.
   PubMed Web of Science ®Google Scholar
• Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(7):767–773.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lu L, Liu S, et al. Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson’s disease. Int J Biochem Cell Biol. 2013;45(2):265–272.
   PubMed Web of Science ®Google Scholar
• Liang YQ, Tang XC. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin. 2006;27(9):1127–1136.
   PubMed Web of Science ®Google Scholar
• Chen LW, Wang YQ, Wei LC, et al. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease. CNS Neurol Disord Drug Targets. 2007;6(4):273–281.
   PubMedGoogle Scholar
• Gersner R, Ekstein D, Dhamne SC, et al. Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition. Epilepsy Res. 2015;117:97–103.
   PubMed Web of Science ®Google Scholar
• Pitler TA, Alger BE. Cholinergic excitation of GABAergic interneurons in the rat hippocampal slice. J Physiol. 1992;450:127–142.
   PubMed Web of Science ®Google Scholar
• Zhong P, Gu Z, Wang X, et al. Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer’s disease. J Biol Chem. 2003;278(29):26888–26896.
   PubMed Web of Science ®Google Scholar
• Hsieh TH, Dhamne SC, Chen JJ, et al. A new measure of cortical inhibition by mechanomyography and paired-pulse transcranial magnetic stimulation in unanesthetized rats. J Neurophysiol. 2012;107(3):966–972.
   PubMed Web of Science ®Google Scholar
• Briggs F, Usrey WM. Patterned activity within the local cortical architecture. Front Neurosci. 2010;4:18.
   PubMedGoogle Scholar
• Jedlicka P, Backus KH. Inhibitory transmission, activity-dependent ionic changes and neuronal network oscillations. Physiol Res. 2006;55(2):139–149.
   PubMed Web of Science ®Google Scholar
• Ravizza T, Balosso S, Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci Lett. 2011;497(3):223–230.
   PubMed Web of Science ®Google Scholar
• Vezzani A, French J, Bartfai T, et al. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31–40.
   PubMed Web of Science ®Google Scholar
• Zattoni M, Mura ML, Deprez F, et al. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J Neurosci. 2011;31(11):4037–4050.
   PubMed Web of Science ®Google Scholar
• Dube C, Vezzani A, Behrens M, et al. Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol. 2005;57(1):152–155.
   PubMed Web of Science ®Google Scholar
• Vezzani A, Balosso S, Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun. 2008;22(6):797–803.
   PubMed Web of Science ®Google Scholar
• Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5(8):629–640.
   PubMed Web of Science ®Google Scholar
• Falip M, Salas-Puig X, Cara C. Causes of CNS inflammation and potential targets for anticonvulsants. CNS Drugs. 2013;27(8):611–623.
   PubMed Web of Science ®Google Scholar
• Hu S, Sheng WS, Ehrlich LC, et al. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation. 2000;7(3):153–159.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ruan X, Zhang S, et al. Effect of interleukin-1 beta on the elevation of cytoplasmic free calcium of the cultured hippocampal neurons induced by L-glutamate. J Tongji Med Univ. 1999;19(2):120–123.
   PubMedGoogle Scholar
• Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr. 2014;14(1 Suppl):3–7.
   PubMed Web of Science ®Google Scholar
• Vezzani A, Aronica E, Mazarati A, et al. Epilepsy and brain inflammation. Exp Neurol. 2013;244:11–21.
   PubMed Web of Science ®Google Scholar
• Maroso M, Balosso S, Ravizza T, et al. Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics. 2011;8(2):304–315.
   PubMed Web of Science ®Google Scholar
• Diamond ML, Ritter AC, Failla MD, et al. IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia. 2014;55(7):1109–1119.
   PubMed Web of Science ®Google Scholar
• Rotenberg A. Commentary on IL-1β associations with posttraumatic epilepsy development: A genetics and biomarker cohort study. Epilepsia. 2015;56(7):989–990.
   PubMed Web of Science ®Google Scholar
• Westerlund A, Bjorklund U, Ronnback L, et al. Long-term nicotine treatment suppresses IL-1beta release and attenuates substance P- and 5-HT-evoked Ca(2)(+) responses in astrocytes. Neurosci Lett. 2013;553:191–195.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang J, Jiang Q. The protective effect of huperzine A against hepatic ischemia reperfusion injury in mice. Transplant Proc. 2014;46(5):1573–1577.
   PubMed Web of Science ®Google Scholar
• Sui X, Gao C. Huperzine A ameliorates damage induced by acute myocardial infarction in rats through antioxidant, anti-apoptotic and anti-inflammatory mechanisms. Int J Mol Med. 2014;33(1):227–233.
   PubMed Web of Science ®Google Scholar
• Mao XY, Cao DF, Li X, et al. Huperzine A ameliorates cognitive deficits in streptozotocin-induced diabetic rats. Int J Mol Sci. 2014;15(5):7667–7683.
   PubMed Web of Science ®Google Scholar
• Tian GX, Zhu XQ, Chen Y, et al. Huperzine A inhibits CCL2 production in experimental autoimmune encephalomyelitis mice and in cultured astrocyte. Int J Immunopathol Pharmacol. 2013;26(3):757–764.
   PubMed Web of Science ®Google Scholar
• Cogswell JP, Godlevski MM, Wisely GB, et al. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol. 1994;153(2):712–723.
   PubMed Web of Science ®Google Scholar
• Tang XC, Xu H, Feng J, et al. Effect of cholinesterase inhibition in vitro by huperzine analogs. Zhongguo Yao Li Xue Bao. 1994;15(2):107–110.
   PubMed Web of Science ®Google Scholar
• Carlier PR, Du DM, Han YF, et al. Dimerization of an inactive fragment of Huperzine A produces a drug with twice the potency of the natural product this work was supported by the Research Grants Council of Hong Kong (HKUST6156/97M), the Biotechnology Research Institute (HKUST), the Mayo Foundation, and the Istituto Pasteur Fondazione Cenci Bolognetti (E.P.). We thank Prof. X. C. Tang (Shanghai Institute of Materia Medica) for a gift of (-)-1. Angew Chem Int Ed Engl. 2000;39(10):1775–1777.
   PubMed Web of Science ®Google Scholar
• Hu S, Wang R, Cui W, et al. Inhibiting β-amyloid-associated Alzheimer’s pathogenesis in vitro and in vivo by a multifunctional dimeric bis(12)-hupyridone derived from its natural analogue. J Mol Neurosci. 2015;55(4):1014–1021.
   PubMed Web of Science ®Google Scholar